Nevro Company Profile
Nevro Corp, a Redwood City-based medical device company with 1,099 employees as of 2024, specializes in its HFX spinal cord stimulation platform—primarily the Senza SCS system for chronic pain treatment—and was acquired by Globus Medical in April 2025 for $253 million after raising a total of $590 million in funding since its 2006 founding.
Overview
Nevro Corp is a medical device company founded in 2006. Its primary product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system—an evidence-based neuromodulation system for the treatment of chronic pain. The Senza system generates electrical impulses to relieve pain, is implanted by physicians, and is controlled by patients. The system consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The majority of the company's revenue is generated in the United States.
- Status: Acquired/Merged
- Employees: 1,099 (as of 2024)
- Latest Deal Type: M&A
- Latest Deal Amount: $253M
- Parent Company: Globus Medical
- Formerly Known As: NBI Development
- Ownership Status: Acquired/Merged (Operating Subsidiary)
- Financing Status: Formerly VC-backed
- Primary Industry: Therapeutic Devices
- Corporate Office: 1800 Bridge Parkway, Redwood City, CA 94065, United States
- Website: www.nevro.com
Valuation & Funding
- Merger/Acquisition: 03-Apr-2025, $253M, Completed, Profitable
- Debt - Acquisition: 30-Nov-2023, Completed, Profitable
- Secondary Transactions (Open Market): 2016-2017, Completed, Generating Revenue
- IPO: 06-Nov-2014, Completed, Generating Revenue
- Later Stage VC (Series C): 08-Feb-2013, $48M, $154M raised to date, Completed, Generating Revenue
- Early Stage VC (Series B): 19-Jul-2011, $58.6M, $106M raised to date, Completed, Startup
Total funding raised: $590M
Cap Table (Partial)
- Series A: 130,508,081 shares authorized, Par Value $0.001, Dividend Rate 8%, Original Issue Price $0.36, Liquidation Preference Multiple 1x, Conversion Price $0.36, 30.35% owned
Comparisons
Nevro Corp is a medical device company specializing in therapeutic devices and headquartered in Redwood City, CA, with 1,099 employees as of 2024.
Competitors (Sample)
- Penumbra (Alameda, CA)
- Spine Wave (Shelton, CT)
- Mainstay Medical (San Diego, CA)
- BioWave (Westport, CT)
- Saluda Medical (Bloomington, MN)
Patents
- Total Documents (Applications and Grants): 866
- Total Patent Families: Not specified
- Granted: 624
- Pending: 64
- Expiring in next 12 months: Not specified
Recent Patent Activity (Sample)
- US-20260137937-A1: Long pulse width spinal cord stimulation for treating autonomic nerve dysfunction, and associated systems and methods (Pending, 18-Nov-2024)
- US-20260151630-A1: Long pulse width spinal cord stimulation for treating autonomic nerve dysfunction, and associated systems and methods (Pending, 18-Nov-2024)
- US-20260115471-A1: Systems and methods for delivering neurostimulation to increase blood glucose uptake in a patient (Pending, 24-Oct-2024)
- WO-2025184547-A1: Apparatus and method for forming a subcutaneous pocket (Pending, 29-Feb-2024, A61B17/3468)
Former Investors (Sample)
- Aberdare Ventures (Venture Capital)
- Accuitive Medical Ventures (Venture Capital)
- Bay City Capital (Venture Capital)
- Johnson & Johnson JJDC (Corporate Venture Capital)
- MPM BioImpact (Venture Capital)
Acquisitions
- Vyrsa Technologies: Acquired on 30-Nov-2023 (Surgical Devices, King of Prussia, PA, founded 2021)
ESG (Environmental, Social, Governance)
- Risk Rating (as of June 4, 2026): 32.61 (High Risk)
- Risk Scale: 0-10 Negligible, 10-20 Low, 20-30 Medium, 30-40 High, 40+ Severe
- Exposure: Refers to the extent to which a company is exposed to different material ESG issues
- Management: Related to actions taken to manage ESG issues
Affiliates
- Subsidiary: Vyrsa Technologies (King of Prussia, PA, founded 2021)
FAQs
When was Nevro founded?
Nevro was founded in 2006.
Where is Nevro headquartered?
Nevro is headquartered in Redwood City, CA.
What is the size of Nevro?
Nevro has 1,099 total employees.
What industry is Nevro in?
Nevro’s primary industry is Therapeutic Devices.
Is Nevro a private or public company?
Nevro is a Private company.
How much funding has Nevro raised over time?
Nevro has raised $590M.
Who are Nevro’s investors?
Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Johnson & Johnson JJDC, and MPM BioImpact are among the investors who have invested in Nevro.
Who are Nevro’s competitors?
Penumbra, Spine Wave, Mainstay Medical, BioWave, and Saluda Medical are some of the competitors of Nevro.
When was Nevro acquired?
Nevro was acquired on 03-Apr-2025.
Who acquired Nevro?
Nevro was acquired by Globus Medical.